Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Elanco Animal Health Incorporated disclosed that Dodge & Cox beneficially owns 68,944,100 shares of its common stock, equal to 13.9% of the class as of 03/31/2026.
The filing is an Amendment No. 5 to a Schedule 13G/A and notes that Dodge & Cox Stock Fund holds 45,270,700 shares (9.1%). The amendment was signed on 05/14/2026.
Elanco Animal Health Incorporated ownership disclosure: PRIMECAP MANAGEMENT CO/CA/ reports beneficial ownership of 45,840,956 shares of common stock, representing 9.22% of the class. The filing lists sole voting power of 45,573,360 shares and sole dispositive power of 45,840,956 shares.
Elanco Animal Health delivered solid top-line growth in the quarter ended March 31, 2026, with revenue rising 15% to $1,371 million, driven by double-digit gains in both pet health and farm animal products across U.S. and international markets.
Despite higher sales, net income declined to $57 million from $67 million, and diluted EPS fell to $0.11, as amortization, restructuring costs and higher interest expense, including on a liability for future royalty sales, weighed on profit. Cash flow from operations turned modestly positive, cash stood at $428 million, and long-term debt remained significant at about $3.9 billion. Elanco advanced its pipeline and strategy with approvals and launches for Zenrelia and Credelio Quattro and closed the AHV farm animal acquisition shortly after quarter end, while progressing its 2025 restructuring plan aimed at margin expansion.
Elanco Animal Health reported a strong first quarter of 2026 and raised its full-year outlook. Revenue was $1,371 million, up 15% year-over-year, with 10% organic constant currency growth. Adjusted EBITDA rose to $334 million, a 21% increase, and adjusted EBITDA margin improved to 24.5%. Reported EPS was $0.11, while adjusted EPS increased to $0.40, up 8% from 2025.
The company raised 2026 revenue guidance to $5,010–$5,085 million, implying 5%–7% organic constant currency growth, and lifted adjusted EBITDA guidance to $975–$1,005 million. Adjusted EPS guidance increased to $1.03–$1.09, with a 13% year-over-year increase at the midpoint. Elanco also improved its year-end net leverage ratio target to 3.0x–3.2x adjusted EBITDA from a current 3.5x.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc officer Rajeev A. Modi reported an award of 65.6122 deferred stock units on May 1, 2026, tied to Company common stock at a reference price of $22.51 per unit. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan. Following this grant, Modi directly holds a total of 9,265.6213 deferred stock units.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health President and CEO Jeffrey N. Simmons received a grant of 125.5855 deferred stock units on May 1, 2026. These units are tied to the company’s common stock at a reference price of $22.51 per unit and are part of his compensation, not an open-market trade. Following this award, his reported deferred stock unit balance is 24,164.1158 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.7526 deferred stock units, each tied to one share of common stock at a reference value of $22.51. After this compensation award, he holds 74.4993 deferred stock units in total.
The deferred stock units represent the right to receive either cash or Elanco common stock in the future. They generally settle after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan, rather than being an open-market stock purchase or sale.
Elanco Animal Health Inc is reported as having 26,138,990 shares beneficially owned by Vanguard Capital Management, representing 5.25% of the outstanding common stock as disclosed in a Schedule 13G. The filing states Vanguard Capital Management has sole dispositive power over all 26,138,990 shares and sole voting power over 3,802,866 shares.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026, and lists Vanguard affiliates and fund holdings as the basis for beneficial ownership. The report notes these holdings reflect securities managed on behalf of Vanguard funds and certain clients.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 119.3805 deferred stock units on April 17, 2026 at a reference price of $23.68 per unit. Following this award, he holds 24,038.5303 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after Simmons’ employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a small compensation-related award of deferred stock units. On this Form 4, he acquired 8.3201 deferred stock units tied to Elanco common stock, bringing his directly held deferred stock unit balance to 65.7467.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.